药品管理新规构建全链条创新激励生态

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, 2026, optimizing the entire drug regulatory system and particularly enhancing the management of traditional Chinese medicine, pediatric drugs, and rare disease medications [1] Group 1: Drug Approval Process - The new regulations institutionalize and legalize the accelerated approval channels for breakthrough therapies, conditional approvals, priority reviews, and special approvals, which were first introduced in the 2020 "Drug Registration Management Measures" [2] - As of December 2025, 395 drug varieties have entered the breakthrough therapy program, 158 have received conditional approval, and 508 have entered the priority review channel, with the average review time for innovative drugs reduced by 25% compared to 2018 [2] - The clarity of the regulatory framework is expected to provide multinational companies with stable policy expectations, encouraging them to increase their investment in China and potentially lead global R&D projects from China [2] Group 2: Market Exclusivity - The new regulations introduce a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, provided that the drug supply is guaranteed [3] - This exclusivity is seen as a reasonable compensation for high-risk investments, which may attract more social capital into underdeveloped but essential areas [3] - The regulations support clinical value-oriented R&D and clarify the fast-track approval process for new drugs, aiming to expedite the availability of effective medications to patients [3] Group 3: Industry Transformation - The revisions are expected to trigger profound changes in China's pharmaceutical industry, pushing domestic companies to transition from low-level fast-follow strategies to high-level original innovation [5] - The competitive landscape is anticipated to shift from local market competition to global market competition, as companies adapt to the new regulatory environment [5] - The new regulations create a comprehensive innovation incentive ecosystem covering the entire drug lifecycle, which is particularly valuable in the context of ongoing challenges in healthcare negotiations and capital markets [4]